Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, discussed findings of 2 phase 4 real-world studies on tildrakizumab, which showed that patients achieved significant improvement in severity and quality of life by week 4 of treatment.
Real-world patients with moderate to severe psoriasis showed significant improvement in severity and quality of life by week 4 of treatment with tildrakizumab, said Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America.
Rozzo served as coauthor of 2 studies presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting, titled “Real-world Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Plaque Psoriasis: Week 28 Interim Analysis of a Phase 4 Study” and “A Phase 4, Real-world Study of Tildrakizumab in Moderate-to-Severe Psoriasis: Week 28 Interim Analysis.”
Can you discuss findings of the phase 4 real-world studies presented at AAD 2022 investigating the impact of tildrakizumab on severity, quality of life in moderate to severe psoriasis?
One of the most encouraging parts, I think, for patients and for providers, is that the clinical efficacy was significantly improved by week 4 after just 1 injection. But also the quality of life, as assessed through the Psychological [General] Well-Being Index, as well as through Dermatology Life Quality Index, which is more familiar to many dermatologists, also showed significant improvement by week 4.
Patients continued to improve and maintained their improvement through week 28. So, this is not something you'll necessarily see all the time in real-world studies. It's very gratifying to see that and see that the results are very consistent with the phase 3 clinical trials.
How has efficacy of tildrakizumab fared across racial/ethnic subgroups in patients with moderate to severe psoriasis?
During our phase 3 trials, we assessed the efficacy and safety across a variety of ethnic and racial groups. And it was good to see that there was no difference. It worked equally well in patients across demographic groups.